AMCP Northwest
I think I blinked and my trip to Portland, Oregon and the Day of Education hosted by AMCP Northwest was here and gone.
Representing the Amyloidosis Research Consortium and joining conversations around ATTR-CM, health disparities, affordability, access, and the real-world patient experience.
One of the strongest parts of the program was the format itself. Clinical insight, managed care, research, and patient perspective all happening in the same conversation instead of separate silos.
Collaborative. Honest. Meaningful.
Thank you for intentionally making space for both the science and the human side of care. That balance matters.
#Amyloidosis #ATTRCM #AMCPNorthwest #HealthEquity #PatientAdvocacy #ManagedCare #Healthcare
Attending the AMCP Northwest event in Portland provided a unique perspective on the challenges and advancements in treating transthyretin amyloidosis cardiomyopathy (ATTR-CM). One aspect that stood out was the deliberate integration of diverse voices—from clinical pharmacists and researchers to patient advocates—ensuring the dialogue covered not only scientific developments but also the human impact of care. In my experience, such interdisciplinary panels fostered a much richer understanding of how to approach complex diseases like ATTR-CM. It became clear that health disparities and access to affordable treatments remain significant barriers for many patients. By bringing managed care professionals and researchers into the same conversation as patients and advocacy groups, AMCP Northwest emphasized the importance of coordinated care that addresses both medical and social determinants of health. Another highlight was how the format encouraged honest conversations about real-world patient experiences, highlighting challenges beyond the lab or clinic. This openness helps identify gaps that may be overlooked in traditional siloed settings. From my personal involvement with amyloidosis communities, patient perspectives are critical for shaping policies that truly meet the community's needs. Moreover, the panel titled "Bridging Regions, Aligning Stakeholders: Advancing Coordinated Care in Transthyretin Amyloidosis Cardiomyopathy" underscored the value of regional collaboration. It reminded me that progress in treating rare diseases like ATTR-CM requires not only scientific innovation but also effective communication and partnership across healthcare providers, payers, and patient groups. Overall, the AMCP Northwest Day of Education reinforced my belief that healthcare is most effective when science and the human side of care are balanced thoughtfully. Events like this encourage continued dialogue that moves beyond data to embrace empathy, equity, and advocacy—key components to improving outcomes for amyloidosis patients.
